|
1
|
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.
|
Ann Rheum Dis
|
2008
|
6.97
|
|
2
|
Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.
|
Blood
|
2000
|
3.60
|
|
3
|
Major histocompatibility complex-restricted, polyclonal B cell responses resulting from helper T cell recognition of antiimmunoglobulin presented by small B lymphocytes.
|
J Exp Med
|
1985
|
2.32
|
|
4
|
Role of membrane immunoglobulin (Ig) crosslinking in membrane Ig-mediated, major histocompatibility-restricted T cell-B cell cooperation.
|
J Exp Med
|
1985
|
1.98
|
|
5
|
Evaluation of pannus and vascularization of the metacarpophalangeal and proximal interphalangeal joints in rheumatoid arthritis by high-resolution ultrasound (multidimensional linear array).
|
Arthritis Rheum
|
1999
|
1.51
|
|
6
|
Exacerbation of Whipple's disease associated with infliximab treatment.
|
Scand J Rheumatol
|
2005
|
1.49
|
|
7
|
Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement.
|
EMBO J
|
1992
|
1.35
|
|
8
|
Characterization of the effector mechanism of help for antigen-presenting and bystander resting B cell growth mediated by Ia-restricted Th2 helper T cell lines.
|
J Immunol
|
1988
|
1.27
|
|
9
|
Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation.
|
EMBO J
|
1993
|
1.14
|
|
10
|
Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report.
|
Lupus
|
2011
|
1.06
|
|
11
|
Antigen presentation by hapten-specific B lymphocytes. IV. Comparative ability of B cells to present specific antigen and anti-immunoglobulin antibody.
|
J Immunol
|
1987
|
1.05
|
|
12
|
Characterization of antigen processing and presentation by resting B lymphocytes.
|
J Immunol
|
1988
|
1.01
|
|
13
|
Stimulation of murine B cells with anti-Ig antibodies: dominance of a negative signal mediated by the Fc receptor.
|
Eur J Immunol
|
1980
|
1.00
|
|
14
|
Vgamma9/Vdelta2 T cell activation induced by bacterial low molecular mass compounds depends on the 1-deoxy-D-xylulose 5-phosphate pathway of isoprenoid biosynthesis.
|
FEMS Immunol Med Microbiol
|
1999
|
0.99
|
|
15
|
Assessment of microvascular changes in Raynaud's phenomenon and connective tissue disease using colour doppler ultrasound.
|
Rheumatology (Oxford)
|
2000
|
0.99
|
|
16
|
Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid.
|
Arch Dermatol Res
|
1996
|
0.94
|
|
17
|
Nuclear NF-ATp is a hallmark of unstimulated B cells from B-CLL patients.
|
Leuk Lymphoma
|
1996
|
0.92
|
|
18
|
Improvement of refractory rheumatoid arthritis after depletion of B cells.
|
Scand J Rheumatol
|
2004
|
0.90
|
|
19
|
Host cell factor CD59 restricts complement lysis of Plasmodium falciparum-infected erythrocytes.
|
Eur J Immunol
|
1997
|
0.87
|
|
20
|
Oligoarthritis mediated by tumor-specific T lymphocytes in renal-cell carcinoma.
|
N Engl J Med
|
1999
|
0.85
|
|
21
|
Atrial ejection force in systemic autoimmune diseases.
|
Cardiology
|
1999
|
0.83
|
|
22
|
STAT6 and the regulation of CD23 expression in B-chronic lymphocytic leukemia.
|
Leuk Res
|
2000
|
0.81
|
|
23
|
Immunological detection of the oestradiol receptor protein in cell lines derived from the lymphatic system and the haematopoietic system: variability of specific hormone binding in vitro.
|
J Endocrinol
|
1992
|
0.77
|
|
24
|
Endothelial cells are the major source of sICAM-1 in rheumatoid synovial tissue.
|
Rheumatol Int
|
1997
|
0.77
|
|
25
|
Inhibition of T cell/B cell interaction by B-CLL cells.
|
Leukemia
|
1999
|
0.75
|
|
26
|
Topoisomerase I-inhibition enhances vitamin D-responsive expression of the receptor for lipopolysaccharide binding protein CD 14.
|
Biochem Biophys Res Commun
|
1994
|
0.75
|
|
27
|
[Sarcoidosis in monozygotic twins].
|
Dtsch Med Wochenschr
|
1995
|
0.75
|
|
28
|
[Systemic sclerosis].
|
Internist (Berl)
|
2006
|
0.75
|
|
29
|
[Rheumatoid arthritis--diagnosis and therapy].
|
MMW Fortschr Med
|
2001
|
0.75
|
|
30
|
[Spondyloarthritis].
|
Internist (Berl)
|
2002
|
0.75
|
|
31
|
[Treatment of patients with acquired (non-HIV) immune deficiencies].
|
Fortschr Med
|
1994
|
0.75
|
|
32
|
[Systemic lupus erythematosus].
|
Internist (Berl)
|
2003
|
0.75
|
|
33
|
[Effects of amalgam on cells of the immune system].
|
Dtsch Zahnarztl Z
|
1991
|
0.75
|
|
34
|
Gamma/delta receptor-expressing T-cell clones from a cutaneous T-cell lymphoma suppress hematopoiesis.
|
Ann Hematol
|
1992
|
0.75
|
|
35
|
[Sensible diagnosis in suspected immune deficiency].
|
Fortschr Med
|
1994
|
0.75
|
|
36
|
[Rheumatic diseases with initial manifestations in middle age: gout, rheumatoid arthritis and ANCA-associated vasculitides].
|
Internist (Berl)
|
2012
|
0.75
|
|
37
|
Anti-Ig as a model for MHC-restricted help.
|
Ann Immunol (Paris)
|
1984
|
0.75
|
|
38
|
Failure to detect any effect of amalgam restorations on peripheral blood lymphocyte populations.
|
Clin Investig
|
1992
|
0.75
|
|
39
|
Persistent polyclonal B-cell lymphocytosis--an important differential diagnosis of B-cell chronic lymphocytic leukemia.
|
Ann Hematol
|
2000
|
0.75
|
|
40
|
An in vitro model for the expansion of V gamma 9 delta 2 T lymphocytes during development.
|
Scand J Immunol
|
1994
|
0.75
|
|
41
|
[NSAIDs and COX-2-inhibitors: current status].
|
Internist (Berl)
|
2006
|
0.75
|
|
42
|
Characterization of an acute T lymphoblastic leukemia expressing the gamma/delta T-cell receptor.
|
Blut
|
1990
|
0.75
|
|
43
|
First-line therapy of advanced chronic lymphocytic leukemia.
|
Leukemia
|
1997
|
0.75
|
|
44
|
Colour Doppler ultrasound of the nailbed: an objective tool for monitoring responses to vasodilatory treatment of connective tissue disorders?
|
Rheumatology (Oxford)
|
2001
|
0.75
|
|
45
|
[Treatment of rheumatoid arthritis (RA) with anticytokines].
|
MMW Fortschr Med
|
2006
|
0.75
|
|
46
|
[Soluble interleukin 2 receptor as activity parameter in serum of systemic and discoid lupus erythematosus].
|
Hautarzt
|
1993
|
0.75
|